- Poster presentation
- Open Access
A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
© Chege et al; licensee BioMed Central Ltd. 2012
- Published: 13 September 2012
- Rhesus Macaque
- Peak Response
- Post Vaccination
- ELISPOT Assay
- Peak Magnitude
We have previously reported induction of robust immune responses in rhesus macaques following a prime boost immunization with candidate HIV-1 vaccines, SAAVI DNA-C (DNA) and SAAVI MVA-C (MVA). These vaccines are already in clinical evaluation. In the current study, we investigated whether re-boosting these animals with a single MVA inoculation after more than 3 years was sufficient to restore previous magnitudes of HIV-specific immune responses.
Seven rhesus macaques which had been vaccinated with three doses of DNA vaccine (4mg DNA/dose) and two doses of MVA (109 pfu MVA/dose) in a past study, >3 years previously, were re-boosted with a single dose of MVA. HIV-1-specific responses were quantified in the peripheral blood using an IFN-gamma ELISPOT assay.
A peak magnitude of response (1146±240 sfu/106 PBMC) was reached 1 week after vaccination with the first dose of MVA. The second MVA inoculation did not increase these responses which declined to undetectable levels by 1 year post vaccination. After re-boosting with MVA after 3.5 years post the second MVA, all animals responded, with a peak response (1824±672 sfu/106 PBMC) being reached 1 week after vaccination. Although the mean magnitude of the second peak was not significantly higher than the one seen in the first peak, boosting of responses in 3 of 7 animals with an apparent broadening of the breadth of responses was observed.
These preliminary data suggest a long-term preservation of vaccine memory following a prime-boost vaccination regimen with SAAVI DNA-C and SAAVI MVA-C vaccines.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.